MB66 Film
Plant produced anti-HIV and anti-HSV antibodies. Phase 1 clinical trial ends Q3 2018. The next generation of MB66 will include an anti-sperm human contraceptive antibody (HCA).
Development Stage:
Clinical – Phase 1 Trial (C1)
Hormonal/Non-Hormonal:
Non-Contraceptive
Delivery Route & Method:
Topical - Film - Vaginal
Mechanism of Action:
virus neutralization, mucus trapping
Developer:
- Mapp Biopharmaceutical, Inc.
Funding:
- DAIDS
- Nat. Institute Allergy & Infect. Diseases (NIAID)
Active Ingredient(s):
- Monoclonal Antibodies
Product Indication(s):
- HIV
- HSV-2
Useful Links:
- http://www.bumc.bu.edu/ipcp/project-1-critical-path-project-mapp66-a-multi-antibody-prevention-product/
- https://www.collectiveip.com/grants/NIH:8302296
- https://www.clinicaltrials.gov/ct2/show/NCT02579083?term=mAb+film&rank=1
- https://www.croiconference.org/abstract/phase-i-placebo-controled-safety-pk-and-pd-study-of-mb66-anti-hiv-and-anti-hsv-film/